Furazolidone, Co-amoxiclav, Colloidal Bismuth Subcitrate, and Esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy
There is increasing evidence of Helicobacter pylori (H. pylori) resistance to the classical triple therapy consisting of a proton-pump inhibitor and clarithromycin with either amoxicillin or metronidazole. This study is aimed at establishing the efficacy and safety of a 14-day regimen to eradicate H. pylori in patients who have failed with the classical triple therapy given for 14 days. One hundred seventy-six patients diagnosed to have H. pylori infection were given triple therapy for 14 days. Fifty-two patients who failed to respond as evident from positive 14C-urea breath test (UBT) done 4–6 weeks after the completion of triple therapy were offered a combination regimen comprised of furazolidone 200 mg b.i.d, co-amoxiclav 1 g b.i.d., colloidal bismuth subcitrate 240 mg b.i.d., and esomeprazole 40 mg b.i.d. for 14 days. The mean age of these patients was 41 ± 13 years (range 20–67). Thirty-four were males. To document eradication of H. pylori, UBT was repeated 4 weeks after the completion of treatment. On an intention-to-treat analysis, the eradication rate was 81% (42 out of 52) whereas on per-protocol basis, the eradication rate was 82.4% (42 out of 51). In conclusion, this new regimen represents a suitable second-line therapy.
Digestive Diseases and Sciences
(2009). Furazolidone, Co-amoxiclav, Colloidal Bismuth Subcitrate, and Esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy. Digestive Diseases and Sciences, 54(9), 1953-1957.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med/154